MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

Phase 2

Completed

• Conditions: Diabetes Mellitus, Type 2; Metabolic Syndrome

• Registration Number: NCT00543595
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2004-08
• Primary Completion: 2005-05
• Study Completion: 2005-05
• Study First Submitted: 2007-10-05
• Study First Submitted QC: 2007-10-12
• Study First Posted: 2007-10-15
• Status Verified: 2015-05
• Last Update Submitted: 2015-05-21
• Last Update Posted: 2015-05-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 154

Inclusion Criteria

• Have Type 2 Diabetes
• 18 to 65 years of age

Read More

Exclusion Criteria

• History of Type 1 Diabetes Mellitus
• Have been treated with insulin in the past 8 weeks
• On a weight loss program and have ongoing weight loss
• Taking weight loss medication
• Have had surgery requiring general anesthesia in the past 30 days or have a planned surgery
• Have taken another investigational drug in the last 8 weeks
• Have active liver disease
• Have a history of major surgery involving gastric or intestinal bypass

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL